FDA Brief

Warning letters Drugs

FDA warning letter to

Chengdu Brilliant Biopharmaceutical Co., Ltd.

High riskIssued Sep 11, 2025Posted Sep 23, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.

What happened

FDA reviewed records the company submitted in response to a March 12, 2025, request for records under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act. FDA found no process validation for the semaglutide API and no identity testing of incoming raw materials for a period redacted in the letter. FDA placed all drugs offered for import from the firm on Import Alert 66-40 on July 9, 2025.

What FDA found

  1. The firm did not perform process validation for its semaglutide API, so it lacks evidence that the process can reproducibly meet quality attributes.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. The firm did not test the identity of each batch of incoming raw material used to make its API during a period redacted in the letter.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

Respond in writing within 15 working days with what you have done to correct the deviations and prevent recurrence, or explain the delay and give a completion schedule. Provide the detailed validation and material-system information requested in the letter.

Who should pay attention

  • drug manufacturers using semaglutide API from this firm
  • companies with products listing this firm as an API manufacturer
  • suppliers and distributors of imported APIs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk